Treatment with Mesenchymal Stem Cells in knee osteoarthritis

Osteoarthritis is a common and degenerative chronic and debilitating joint disease.

It is known that approximately 30% of the world population over 60 years of age suffer osteoarthritis. Currently, treatment options focus on providing temporary pain relief and reducing inflammation during the early stages of the disease without affecting the course of the disease.

Given this, the need arises for new alternatives as possible treatments in diseases such as osteoarthritis. The scientific community focuses on the study of therapies based on stem cells to address the repair of damaged cartilage in the knee joint. It has been observed that mesenchymal stem cells are responsible for the rotation and maintenance of cells in various adult tissues, including cartilage.

A preclinical study was carried out with rats to which a picture of joint damage was created; the efficacy and safety of the application of mesenchymal stem cells (Stempeucel) was evaluated. The results obtained were satisfactory, opening the guideline for a clinical study in patients with osteoarthritis. After the application, pain reduction was evaluated, and an MRI was performed to evaluate cartilage conditions.

As part of the results, none of the doses showed ectopic tumor or tissue formation during the study follow-up. They show a pain improvement of up to 64%, therefore, there was improvement in stiffness and physical function according to the scores.

Stempeucel® mesenchymal stem cells in osteoarthritis, demonstrated a significant reduction in pain and inflammation in patients treated with a dose of 25 million cells, it was also demonstrated that these cells have a capacity to regenerate cartilage.

Pawan Kumar Gupta1 *, Anoop Chullikana1, Mathiyazhagan Rengasamy1, Naresh Shetty2, Vivek Pandey3, Vikas Agarwal4, Shrikant Yeshwant Wagh5, Prasanth Kulapurathu Vellotare1, Devi amodaran1, Pachaiyappan Viswanathan1, Charan Thej1.6, Sudha Balasubramanian1 and Anish Sen Majumdar1 *, Efficacy and safety in the use of mesenchymal cells of allogeneic bone marrow (Stempeucel): preclinical and clinical studies in osteoarthritis of the knee, NCT01453738